Press Releases

 
Press Releases
  Date Title and Summary View
Dec 14, 2006
Cranbury, NJ, DECEMBER 14, 2006 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that it has commenced Phase 1 clinical trials for AT2220 for the treatment of Pompe disease, following acceptance of an inve...
PDF
Oct 2, 2006
Cranbury, NJ, October 2, 2006 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced the appointment of James E. Dentzer as Chief Financial Officer (CFO). Mr. Dentzer joins Amicus from Biogen Idec In...
PDF
Sep 20, 2006
Cranbury, NJ, September 20, 2006 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced that studies of the mechanism of action of its investigational treatment for Gaucher disease were published in t...
PDF
Sep 14, 2006
Cranbury, NJ, September 14, 2006 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced the closing of a $60 million Series D financing, the Company's largest to date, led by New Enterprise Associates...
PDF
Jul 5, 2006
Cranbury, NJ, July 5, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced the appointment of Glenn P. Sblendorio to its Board of Directors. Mr. Sblendorio will serve as the financial expert on t...
PDF
May 17, 2006
Cranbury, NJ, May 17, 2006 - Amicus Therapeutics, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. All shares in the offering will be sold by Amicus Therapeutics. Morgan Stanley will act as sole bo...
PDF
Apr 27, 2006
Cranbury, NJ, APRIL 27, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that it has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for AT2101 for th...
PDF
Apr 27, 2006
Cranbury, NJ, APRIL 27, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that it has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for AT2101 for...
PDF
Apr 11, 2006
Cranbury, NJ, April 11, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) has recommended orphan medicinal ...
PDF
Mar 31, 2006
Cranbury, NJ, March 31, 2006 - Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-delivered pharmacological chaperones for the treatment of human genetic diseases, today announced the appointment of Donald J. Hayden, Jr. as executive chairman of the company's Board of Directors. Mr. Hayden brings to Amicus the ...
PDF
Page: FirstPrevious ...
32
NextLast